A Food and Drug Administration advisory panel will consider Tuesday whether Evista, an osteoporosis drug, should be approved to lower breast cancer risk in some women.At least two women’s health advocacy groups oppose such a move, and, in a briefing document for the panel, FDA scientists question whether Evista’s benefits outweigh its risks. The FDA usually follows advisory committee recommendations.